While Takeda's Qdenga (TAK-003) shot is approved as a two-dose regimen to protect people from the disease in dozens of countries around the world, the drugmaker withdrew its FDA filing in mid-2023 ...

Nuvation Bio is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment ...

The companies have said they will create customised AI models and agents that Novo Nordisk can use for early research and ...

Type of data available on UK Pharmascan registration, with a breakdown on whether the live record is for a new indication, ...

At ASCO 2025, BioNTech presented 7 abstracts on four selected pipeline candidates in mesothelioma, lung cancer, prostate cancer, and melanoma.

If that sounds like the storyline to Marvel's latest superhero tale, that's because it is. The publisher's latest custom ...

The rate for the latter half of the year brings the full-year average to 23.4% – rising to 24.3% next year and 26% in 2027 – ...

The pressure to execute a flawless drug or therapy launch has never been greater and continues to lay the foundation for long ...

BMS kickstarted its radiopharma drive last year when it completed a $4.1 billion acquisition of San Diego-based RayzeBio, ...

SpliceBio's lead in-house pipeline project is in Stargardt disease, an IRD with no approved therapies that is caused by ...

Makary and Prasad also repeat various themes repeatedly visited by Kennedy on his Make America Healthy Again (MAHA) soapbox, ...

New research reveals some significant imbalances between healthcare professionals' (HCP) demand and industry's provision of medical information, based on content types, channels and format.